👉An interesting paper :

"HERV-W ENV antigenemia and correlation of increased anti-SARS-CoV-2 immunoglobulin levels with post-COVID-19 symptoms."

" (...) The present study shows, for the first time, that the HERV-W ENV protein can still be actively expressed long after SARS-CoV-2 infection is resolved in post-COVID-19 condition patients.(...)"

There's a P2 clinical trial enrolling:

https://clinicaltrials.gov/ct2/show/NCT05497089

#Post-Covid #LongCovid #SARS-CoV-2 #Retrovirus #PHERV-W env #Temelimab #ClinicalTrial

Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome - Full Text View - ClinicalTrials.gov

Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome - Full Text View.

Bonjour,

Pour le #CovidLong on parle dans cette courte vidéo de l'essai clinique de #phase2 en cours ciblant la #pHERV-w enveloppe chez certains malades ayant eu la #COVID19

🔗🔽

En 🇫🇷
https://youtu.be/ulIOVKTfjME

En 🇬🇧 https://youtu.be/OwbC5e0c_7k

En 🇪🇸
https://youtu.be/03WYfkwC-zs

#Après-J20

🔗 Lien vers l'étude/ The study
https://twitter.com/iguessous/status/1591705247474454528?t=t9eCU0RA_N27iYjRbh53nw&s=19

🔗email : [email protected]

VOIR aussi l'annonce du recrutement des premiers patients dans l'essai (16 octobre 2022)

RT 🐦:https://twitter.com/TinaMey90814508/status/1592777012099239936?t=7wZVuw8UoyoeyK96zftSIA&s=19

Approche de médecine personnalisée contre le COVID-long (FR)

YouTube